Bad Vilbel, Germany – 09 January 2025 | At the turn of the year, STADA's owners Cinven and Bain Capital are setting the course for the company’s future. While no final decision has been made, various options are under consideration, including a potential initial public offering (IPO). In the event of an IPO, STADA’s Board of Directors will be established as the top leadership body, with Andreas Fibig to assume the role of independent Chairman.

With Andreas Fibig, STADA secures an internationally respected executive with deep expertise in the pharmaceutical and consumer healthcare sectors.  
 

The 62-year-old former CEO of International Flavors & Fragrances Inc. (NYSE: IFF) would bring a proven track record of driving strong growth and successful transformation. During his tenure – including seven years as Chairman and CEO – he led IFF through major strategic transitions, including the integration of DuPont Nutrition & Biosciences.

Prior to that, he served as President and Chairman of the Board of Management at Bayer HealthCare Pharmaceuticals, overseeing Bayer’s global healthcare and pharmaceutical operations. He currently serves on the Board of Directors of Novo Nordisk A/S (NYSE: NVO) and is a member of its Research and Development Committee, as well as on the Board of ExlService Holdings, a leading global data analytics and digital solutions provider.

Peter Goldschmidt, CEO of STADA, commented: “Andreas Fibig is an excellent choice for the role of Chairman of the Board of Directors of STADA. His global experience and outstanding expertise, particularly in the healthcare sector, would bring tremendous value to our company. Andreas also shares our belief that 'Culture drives Performance'. I look forward to working with him”. 

Andreas Fibig stated: “I am very honored to assume the role of Chairman of the Board of Directors at STADA in the event of an IPO. With its broad and strong product portfolio, STADA is one of the fastest-growing companies in Consumer Healthcare and a major player in Generics and Specialty Pharmaceuticals. I am especially impressed by the growth-oriented culture under Peter Goldschmidt and his team”.

The Board of Directors will be formed under STADA’s future listed group holding company, to be incorporated under Dutch law and based in Germany. It will comprise the Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of STADA as Executive Directors, along with seven Non-Executive Directors, including the Chairman, who will serve supervisory functions.

 

Disclaimer:

This communication is not intended for publication or distribution, in whole or in part, directly or indirectly, into the United States, including its territories, any U.S. state, or the District of Columbia. It does not constitute an offer or solicitation to sell or subscribe for securities in the United States, Australia, Canada, Japan, or any jurisdiction where such actions would be unlawful.

Any securities referenced have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the U.S. without registration or an applicable exemption.

About STADA Arzneimittel AG:

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy: consumer healthcare products, generics, and specialty pharmaceuticals. STADA sells its products in over 100 countries. In 2023, STADA recorded revenues of EUR 3,734.8 million and EBITDA of EUR 802.1 million. As of December 31, 2023, the company employed 11,667 people worldwide.

Media Contact

STADA Arzneimittel AG – Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-165 | Email: press@stada.de | Website: www.stada.com/press

Investor Contact

STADA Arzneimittel AG – Investor & Creditor Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689 |Email: ir@stada.de | Website: www.stada.com/investor-relations